METHODS: In this single-center prospective cross-sectional study, 35 eyes from 35 patients with POAG or OHT (study group) and 26 age- and gender- matched healthy individuals (control group) were included. All participants were examined by spectral domain optical coherence tomography (SD-OCT) with enhanced depth imaging (EDI) mode for LC thickness and depth measurements at the first visit before latanoprost therapy and at visits after 1 (second visit) and 3 (third visit) months of latanoprost therapy.
RESULTS: The mean LC thickness in both horizontal and vertical scans of the study group were thinner than the control group (p < 0.001, for both). During latanoprost therapy in the study group, the LC thickness values in horizontal scans significantly differed over the three visits, gradually increased (p < 0.05). There was significantly decrease in LC depth in horizontal scans between the first and third visits, and the second and third visits (p = 0.003 and p = 0.008, respectively). The gradual decrease in LC depth in vertical scans was observed at all visits, but the statistically significant difference was between the first and third visits only (p = 0.048).
CONCLUSIONS: POAG/OHT patients showed more LC thinning compared with healthy individuals. The significant increase in LC thickness and the significant decrease in LC depth were detected after IOP reduction therapy with latanoprost in ocular hypertensive/ glaucomatous eyes.
方法:在这项单中心前瞻性横断面研究中,纳入35例POAG或OHT患者(研究组)和26例年龄和性别匹配的健康个体(对照组)的35只眼。所有参与者均通过光谱域光学相干断层扫描(SD-OCT)和增强深度成像(EDI)模式进行检查,以在拉坦前列素治疗前首次就诊以及在拉坦前列素治疗后1(第二次就诊)和3(第三次就诊)个月后进行LC厚度和深度测量。
结果:研究组的水平和垂直扫描的平均LC厚度均比对照组薄(两者均p<0.001)。在研究组的拉坦前列素治疗期间,水平扫描中的LC厚度值在三次访问中显著不同,逐渐升高(p<0.05)。在第一次和第三次就诊之间的水平扫描中LC深度显著降低,以及第二次和第三次访问(分别为p=0.003和p=0.008)。在所有访问中都观察到垂直扫描中LC深度的逐渐减少,但统计学上的显著差异仅在第一次和第三次就诊之间(p=0.048).
结论:与健康个体相比,POAG/OHT患者表现出更多的LC变薄。用拉坦前列素降低眼压治疗眼高血压/青光眼后,LC厚度显着增加,LC深度显着降低。